Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors

Keyphrases

• Tyrosine Kinase Inhibitor 100%
• Chronic Myeloid Leukemia 100%
• Clinical Trials 33%
• Ponatinib 33%
• Class Effect 33%
• Adverse Effects 16%
• Tyrosine Kinase 16%
• Adverse Events 16%
• Toxicity Profile 16%
• Adjudication 16%
• Comprehensive Evaluation 16%
• Sufficient Follow-up 16%
• Inconsistency 16%
• Adverse Event Reporting 16%
• Comprehensive Approach 16%
• Rate of Increase 16%
• Imatinib 16%
• Uniform Approach 16%
• Molecular Response 16%
• Event-based 16%
• Reporting Criteria 16%
• Frequency Threshold 16%
• Medical Dictionary for Regulatory Activities (MedDRA) 16%
• Full Assessment 16%
• Additional Roles 16%
• Real Risk 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Protein Tyrosine Kinase Inhibitor 100%
• Chronic Myeloid Leukemia 100%
• Adverse Event 50%
• Clinical Trial 33%
• Ponatinib 33%
• Protein Tyrosine Kinase 16%
• Imatinib 16%
• MedDRA 16%